COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network

Charlotte Laniece Delaunay, Nuno Verdasca, Susana Monge, Lisa Domegan, Noémie Sève, Silke Buda, Adam Meijer, Héloïse Lucaccioni, Miriam López Torrijos, Adele McKenna, Vincent Enouf, Ralf Dürrwald, Eline In't Velt, Mª Ángel de Valcárcel Laiglesia, Charlene Bennett, Shirley Masse, Annika Erdwiens, Mariette Hooiveld, Ivan Mlinarić, Gergő Túri, Ana Paula Rodrigues, Iván Martínez‐Baz, Mihaela Lazar, Neus Latorre‐Margalef, Vitor Borges, Marlena Kaczmarek, Sabrina Bacci, Esther Kissling, Unknown

Open source

DOI
10.1111/irv.70120
Published
2025-05
Container
Influenza and Other Respiratory Viruses
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/irv.70120,
  title = {COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network},
  author = {Charlotte Laniece Delaunay and Nuno Verdasca and Susana Monge and Lisa Domegan and Noémie Sève and Silke Buda and Adam Meijer and Héloïse Lucaccioni and Miriam López Torrijos and Adele McKenna and Vincent Enouf and Ralf Dürrwald and Eline In't Velt and Mª Ángel de Valcárcel Laiglesia and Charlene Bennett and Shirley Masse and Annika Erdwiens and Mariette Hooiveld and Ivan Mlinarić and Gergő Túri and Ana Paula Rodrigues and Iván Martínez‐Baz and Mihaela Lazar and Neus Latorre‐Margalef and Vitor Borges and Marlena Kaczmarek and Sabrina Bacci and Esther Kissling and Unknown},
  year = {2025},
  journal = {Influenza and Other Respiratory Viruses},
  doi = {10.1111/irv.70120},
  url = {https://doi.org/10.1111/irv.70120}
}

RIS

TY  - JOUR
TI  - COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network
AU  - Charlotte Laniece Delaunay
AU  - Nuno Verdasca
AU  - Susana Monge
AU  - Lisa Domegan
AU  - Noémie Sève
AU  - Silke Buda
AU  - Adam Meijer
AU  - Héloïse Lucaccioni
AU  - Miriam López Torrijos
AU  - Adele McKenna
AU  - Vincent Enouf
AU  - Ralf Dürrwald
AU  - Eline In't Velt
AU  - Mª Ángel de Valcárcel Laiglesia
AU  - Charlene Bennett
AU  - Shirley Masse
AU  - Annika Erdwiens
AU  - Mariette Hooiveld
AU  - Ivan Mlinarić
AU  - Gergő Túri
AU  - Ana Paula Rodrigues
AU  - Iván Martínez‐Baz
AU  - Mihaela Lazar
AU  - Neus Latorre‐Margalef
AU  - Vitor Borges
AU  - Marlena Kaczmarek
AU  - Sabrina Bacci
AU  - Esther Kissling
AU  - Unknown
PY  - 2025
JO  - Influenza and Other Respiratory Viruses
DO  - 10.1111/irv.70120
UR  - https://doi.org/10.1111/irv.70120
ER  - 

APA

Delaunay, C. L., Verdasca, N., Monge, S., Domegan, L., Sève, N., Buda, S., Meijer, A., Lucaccioni, H., Torrijos, M. L., McKenna, A., Enouf, V., Dürrwald, R., Velt, E. I., Laiglesia, M. Á. D. V., Bennett, C., Masse, S., Erdwiens, A., Hooiveld, M., Mlinarić, I., Túri, G., Rodrigues, A. P., Martínez‐Baz, I., Lazar, M., Latorre‐Margalef, N., Borges, V., Kaczmarek, M., Bacci, S., Kissling, E., & Unknown (2025). COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70120

Source records